A novel compound and method for preventing or treating neurodegenerative diseases by inhibiting acetylcholinesterase and binding the sigma-1 receptor are disclosed. Dimethylcarbamic acid 2,3-bis-dimethylcarbamoyloxy-6-[4-(4-ethyl-piperazin-yl)-butyryl]-phenyl ester and its derivatives represent a novel therapeutic strategy against β-amyloid peptide induced neurotoxicity, in inhibiting acetylcholinesterase, in improving cholinergic transmission, in binding the sigma-1 receptor, and in releasing a metabolite that is active both as a sigma-1 receptor ligand and an antioxidant.
本研究公开了一种通过抑制
乙酰胆碱酯酶和结合 sigma-1 受体来预防或治疗神经退行性疾病的新型化合物和方法。
二甲基氨基甲酸 2,3-双-二甲基
氨基甲酰氧基-6-[4-(4-乙基-
哌嗪基)-丁酰基]-苯基酯及其衍
生物在抑制
乙酰胆碱酯酶、改善
胆碱能传导、结合σ-1 受体以及释放一种既是σ-1 受体
配体又是
抗氧化剂的活性代谢物方面,代表了一种针对 β 淀粉样肽诱导的神经毒性的新型治疗策略。